The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced human cancer. Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies.
Neal Rosen, MD, PhD
Research FocusPharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
EducationMD, PhD, Albert Einstein College of Medicine
- Rodrik-Outmezguine V, Okaniwa M, Yao Z, Novotny C, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt D, Cosulich S, Klinowska T, Rosen N* and Shokat K*. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature, 2016; DOI: 10.1038/nature17963.*co-corresponding authors.
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Science. 2016 Feb 5;351(6273):604-8. doi: 10.1126/science.aad6204. Epub 2016 Jan 14.